Category Archives: In-vitro Platform

Tapping into Pluripotent Differentiation Potentials of Embryonic Stem Cells

Posted on January 9, 2016

Using the pluripotent embryonic stem cells as a model system, scientists at NCCS are investigating the epigenetic factors and molecular determinants which are involved in deciding and controlling differentiation of stem cells into specific cellular lineages. Continue reading →

Posted in Biopharma, Cell Therapy, Genetics, In-vitro Platform, Regenerative medicine, Stem Cells

Tagged

An Elegant Model for Studying Early Embryonic Development

Posted on January 9, 2016

Scientists at NCCS are studying the early embryonic development using embryonic stem cells derived from the blastula stage embryo. These embryonic stem cells possess unique characteristics of indefinite self renewal and pluripotency; and are capable of precisely recapitulating the early embryogenic development, thereby serving as an elegant model for studying the developmental events occurring during embryogenesis. Continue reading →

Posted in Biopharma, Cell Therapy, Genetics, In-vitro Platform, Stem Cells

Tagged

Self-propagating Glioblastoma Model in a Petri-dish

Posted on November 3, 2015

Scientists at NCCS have developed a novel tumor cell co-culture protocol and system for understanding the role of glioma stem cells (GSC) in mediating tumor functions in Glioblastoma (GBM). GBM is a highly invasive malignant tumor with high incidence of therapy resistance and tumor relapse after surgery. This relapse is due to repopulation of tumor by GSCs and is characterized by existence of GSCs in close proximity with endothelial cells (EC). In order to study the GSC-EC interactions, this innovative self-propagating GSC-EC co-culture system was developed as a highly replicating in-vitro model of GBM. Continue reading →

Posted in Biopharma, Cancer Biology, In-vitro Platform, Stem Cells

Tagged

Glut-4 Activity based Anti-Diabetic Drug Screening System

Posted on October 14, 2015

Scientists at NCCS have developed an in-vitro anti-diabetic drug screening system based on glucose transporter 4 (GLUT4) activity in a novel cell line (CHO-HIRc-mycGLUT4eGFP). Using this system, GLUT4 translocation under stimulation can be visualized by live cell imaging and captured real-time for qualitative and quantitative analysis of GLUT4 on the cell membrane. Continue reading →

Posted in Biopharma, In-vitro Platform, Metabolic Diseases

Tagged

Platform for Identifying Heterogeneity of Cancer Cells

Posted on October 14, 2015

Cancer cells remaining undetected in the body following treatment regimens can cause recurrence. Recent studies suggest that this debilitating issue could be a result of heterogeneous characteristics of cancer cells; thus residual cells are likely to be drug resistant and/or not targeted by the initial treatment. Scientists at NCCS believe that identifying the heterogeneity of the cancer cells and providing a targeted therapy specific for different cell fractions can resolve this issue. Continue reading →

Posted in Biopharma, Cancer Biology, In-vitro Platform, Stem Cells

Tagged

Novel Cancer Drug Screening Platform

Posted on October 13, 2015

Scientists at NCCS have developed a novel platform for screening of potential anti-tumor agents, compounds and extracts, based on 3-dimensional Multi-Cellular Spheroids derived from tumor cells and prostate apoptosis response (PAR)-4 indicator that is linked to cell death. Continue reading →

Posted in Biopharma, Cancer Biology, In-vitro Platform, Stem Cells

Tagged

In-vitro Bone Marrow Niche Platform and Pre-clinical Screening Kit

Posted on October 3, 2015

An artificial bone marrow microenvironment (ABME) platform for enhancing and regulating in-vitro as well as in vivo formation of stem cells has been created by scientist at NCCS, Pune. This technology can be incorporated into high throughput and micro-fluidic devices for drug screening and in-vitro toxicology testing. Continue reading →

Posted in Biopharma, Cell Therapy, In-vitro Platform, Regenerative medicine, Stem Cells, Umbilical Cord Blood Banking

Tagged

An Overview of NCCS Capabilities

Posted on September 19, 2015
Capability Area NCCS Scientists/ Consultants
Cancer Biology Dr. Sharmila Bapat, Dr. Padma Shastry, Dr. Anjali Shiras, Dr. Mohan Wani, Dr. Gopal Kundu, Dr. Samit Chattopadhyay, Dr. Manoj Kumar Bhat, Dr. Sandhya Sitaswad, Dr. Girdhari Lal, Dr. Srikanth Rapole, Dr. Manas Santra
Cell Biology Dr. Shekhar Mande, Dr. Mohan Wani, Dr. Debashis Mitra, Dr. Prakash Deshpande, Dr. Jomon Joseph,  Dr. Bhaskar Saha, Dr. Milind Patole, Dr. Arvind Sahu, Dr. M. V. Krishnasastry, Dr. Vasudevan Seshadri, Dr. Radha Chauhan, Dr. Janesh Kumar, Dr. Girdhari Lal, Dr. Shailza Singh, Dr. Deepa Subramanyam
Genetics Dr. Sharmila Bapat, Dr. Anjali Shiras, Dr. Samit Chattopadhyay, Dr. Jomon Joseph, Dr. Vasudevan Seshadri, Dr. Manas Santra, Dr. Vidisha Tripathi
Immunology  Dr. Mohan Wani, Dr. Bhaskar Saha, Dr. Arvind Sahu, Dr. Girdhari Lal, Dr. Shailza Singh
Metabolic Diseases Dr. Manoj Kumar Bhat, Dr. Sandhya Sitaswad
Microbial Biology Dr. Milind Patole, Dr. Yogesh Shouche, Dr. Shailza Singh
Neuroscience Dr. Amitabha Majumdar, Dr. Janesh Kumar
Stem Cells Dr. Vaijayanti Kale, Dr. Lalita Limaye, Dr. Anjali Shiras, Dr. Nibedita Lenka, Dr. Deepa Subramanyam

Posted in Biopharma, Cancer Biology, Cell Biology, Cell Therapy, Diagnostics, Genetics, Immunology, In-vitro Platform, Medical Device, Metabolic Diseases, Microbial Biology, Neuroscience, Nutraceutical, Regenerative medicine, Stem Cells, Umbilical Cord Blood Banking

Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,